-
-
-
-
-
-
-
AXIM® Biotechnologies Begins Pre-Clinical Pharmacokinetic Animal Drug Studies on its Cancer Drug Compound SPX-1009
-
-
-
-
-
-
-
AXIM® Biotechnologies Files New U.S. Patent Application for Water-Soluble Cannabinoid Molecules
-
-
-
-
-
-
-
Axim® Biotechnologies Completes First Phase of Pharmacokinetic Clinical Study on Cannabinoid-Based Gum With Dronabinol
-
-
-
-
-
-
-
AXIM® Biotechnologies Nutraceutical Division Announces Cannabinoid-Based Wellness Gum Product Line at Benzinga Cannabis Capital Conference
-
-
-
-
-
-
-
AXIM® Biotechnologies Receives Seventh Private Label Gum Purchase Order Pushing Orders to Nearly $900,000 for Last Five Months
-
-
-
-
-
-
-
Medical Marijuana, Inc. Major Investment Company Axim® Biotechnologies Files New U.S. Provisional Patent for Cannabis Gum as a Treatment for Migraine Symptoms
-
-
-
-
-
-
-
AXIM® Biotechnologies, Inc. Appoints Mauricio Javier Gatto-Bellora to Company’s Board of Directors
-
1,217,881 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

